Calithera Biosciences Inc. (CALA)

Trade CALA now with
7/2/2019 8:20:12 AM Calithera Biosciences Begins Phase 1/2 Trial Of Telaglenastat In Combination With Pfizer’s CDK4/6 Inhibitor Palbociclib
6/17/2019 6:11:47 AM Calithera Biosciences Reports Positive Results From Randomized Phase 2 ENTRATA Study Of Telaglenastat With Everolimus
3/26/2019 7:11:38 AM Calithera Biosciences Initiates Phase 1/2 Trial Of Telaglenastat In Combination With PARP Inhibitor Talazoparib
2/4/2019 7:07:37 AM Calithera Biosciences Completes Patient Enrollment In Randomized Phase 2 ENTRATA Trial Of Telaglenastat And Everolimus
1/7/2019 7:21:30 AM Calithera Provides Corporate Updates, Incl Q4 Financial Results, Financial Guidance And Corporate Milestones For 2019
6/4/2018 8:18:11 AM Calithera Biosciences Announces Clinical Data From Lead Product Candidate CB-839
4/18/2018 7:05:19 AM Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 In Combination With Cabozantinib
10/5/2017 7:37:55 AM William Blair Initiates Calithera Biosciences Inc. (CALA) At Outperform
1/24/2017 10:01:12 AM Citigroup Ups Calithera Biosciences Inc. (CALA) To neutral From sell With -- Price Target